IL6 and congenital rubella syndrome: To cope with these life-threatening side effects, the current strategy includes pharmacological interventions, such as anti-IL-6R mAb (tocilizumab), anti-IL-6 mAb (siltuximab) or corticosteroids, and supportive care depending on the CRS grade (46).